We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
01 Mar 2023 - 03 Mar 2023

Liquid Biopsy Assay Predicts if Esophageal Cancer Patients Will Respond to Treatment

By LabMedica International staff writers
Posted on 17 Jun 2022
Print article
Image: A liquid biopsy can determine if a patient with esophageal cancer will respond to certain treatments (Photo courtesy of Pexels)
Image: A liquid biopsy can determine if a patient with esophageal cancer will respond to certain treatments (Photo courtesy of Pexels)

Biomarkers are like the X on a treasure map, but instead of indicating the location of unearthed riches, they indicate an individual’s health status. Common biomarkers include certain RNA or protein molecules present in tissues and body fluids that can show doctors that a patient has a specific disease or may respond well to a particular treatment plan. Liquid biopsies are appealing as a non-invasive method for measuring biomarker levels in a body fluid. A team of researchers has now designed such a method for predicting patient outcomes following treatment for esophageal squamous cell carcinoma (ESCC), an aggressive and deadly disease.

Surgery is the typical treatment method for ESCC, but recent research has shown that adding neoadjuvant therapy (NAT) can improve patient survival rates. NAT involves shrinking a tumor using approaches such as chemotherapy or radiation prior to surgery. However, not all patients are responsive to NAT. Unnecessarily performing it can take time for these patients and lead to worse outcomes. Therefore, the team of researchers from Tokyo Medical and Dental University (TMDU, Tokyo, Japan) aimed to identify biomarkers and characteristics that could preemptively indicate an ESCC patient’s response to NAT.

To do this, the team obtained 128 ESCC tissue samples and 58 matched serum samples from two clinical institutions. The serum was obtained prior to any treatment. NAT for these patients involved chemotherapy with 5-fluorouracil and cisplatin, followed by surgery 3 to 5 weeks later. Pathologists then analyzed the surgical specimens for residual tumor cells, which helped them categorize these ESCC patients as completely, partially, or non-responsive to NAT.

After the researchers analyzed their data, they concluded that their panel of mRNAs and microRNAs had significant predictive potential. Interestingly, combining the panel with tumor size data further increased the predictive power. mRNA/microRNA signature was the most effective clinical characteristic amongst various combinations. It worked in both early- and advanced-stage ESCC patients. Overall, the liquid biopsy developed by the researchers may serve as a non-invasive method for predicting ESCC patient response to NAT. This can lead to precision medicine approaches that will significantly improve the prognosis of many patients who have this disease.

“Molecular biomarkers can be extremely useful when making clinical decisions,” said lead author of the study Keisuke Okuno. “We also wanted to translate these biomarkers into an easy-to-use liquid biopsy.

“We then examined these patient samples for expression levels of molecules that included three mRNAs and four microRNAs,” added Ajay Goel, senior author of the article. “In previous studies, this panel of mRNAs and microRNAs was found to effectively predict ESCC patient response to NAT.”

“We then utilized the pre-treatment serum samples to translate this signature into a liquid biopsy assay, and our approach still maintained its strong ability to predict response to NAT,” explained Okuno.

Related Links:
TMDU 

New
Platinum Supplier
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
New
Human Papillomavirus (HPV) Test
S3108E HPV G23
New
Human IgE Immunochromatography Test
ImmuneCheck IgE
New
Influenza A Immunoassay
Proflow Influenza A Test

Print article
MEDLAB - INFORMA

Channels

Immunology

view channel
Image: Scientists have won USD 9.5 million to study emerging pathogens (Photo courtesy of Pexels)

Study of Emerging Pathogens to Better Understand Influenza-Antibody Interactions Could Improve Diagnostics

Outbreaks of Avian influenza have occurred around the world for over a century. The highly pathogenic H5N1 virus which was first identified in 1996 can lead to severe disease and has a high fatality rate... Read more

Microbiology

view channel
Image: Medical illustration of Carbapenem-resistant Enterobacteriacea (Photo courtesy of CDC, Stephanie Rossow)

Breakthrough Test Enables Targeted Antibiotic Therapy for Various Enterobacter Species

Bacteria of the Enterobacter genus are considered to be the most dangerous bacteria linked to hospital infections across the world. Some of their representatives demonstrate high resistance to commonly-used... Read more

Technology

view channel
Image: Flexible copper sensor made cheaply from ordinary materials (Photo courtesy of University of São Paulo)

Low-Cost Portable Sensor Detects Heavy Metals in Sweat

Heavy metals like lead and cadmium can be found in batteries, cosmetics, food and many other things that have become a part of daily life. However, they become toxic if they accumulate in the human body... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.